This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Pediatrix Medical Group (MD), Certara (CERT) and Gilead Sciences (GILD)

Tipranks - Tipranks - Wed Aug 5, 9:42AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pediatrix Medical Group (MD), Certara (CERT) and Gilead Sciences (GILD).

Claim 55% Off TipRanks

Pediatrix Medical Group (MD)

William Blair analyst Ryan Daniels maintained a Buy rating on Pediatrix Medical Group today. The company’s shares closed last Tuesday at $25.73.

According to TipRanks.com, Daniels is a 4-star analyst with an average return of 4.4% and a 45.2% success rate. Daniels covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Lifestance Health Group, and Alignment Healthcare. ;'>

The word on The Street in general, suggests a Hold analyst consensus rating for Pediatrix Medical Group with a $26.67 average price target, a 13.2% upside from current levels. In a report released today, TipRanks – OpenAI also reiterated a Buy rating on the stock with a $29.00 price target.

See the top stocks recommended by analysts >>

Certara (CERT)

In a report released today, Jared Haase from William Blair reiterated a Hold rating on Certara. The company’s shares closed last Tuesday at $7.20.

According to TipRanks.com, Haase is a 4-star analyst with an average return of 14.7% and a 74.2% success rate. Haase covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Aveanna Healthcare Holdings, and Definitive Healthcare Corp. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Certara with a $7.79 average price target, which is a 23.0% upside from current levels. In a report released today, Craig-Hallum also maintained a Hold rating on the stock.

Gilead Sciences (GILD)

Truist Financial analyst Gregory Renza maintained a Buy rating on Gilead Sciences today. The company’s shares closed last Tuesday at $131.01.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 18.0% and a 53.3% success rate. Renza covers the Healthcare sector, focusing on stocks such as Perspective Therapeutics, Abivax SA Sponsored ADR, and Viridian Therapeutics. ;'>

Gilead Sciences has an analyst consensus of Strong Buy, with a price target consensus of $159.29, implying a 21.5% upside from current levels. In a report issued on July 22, Bernstein also maintained a Buy rating on the stock with a $160.00 price target.

Read More on MD:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).